trending Market Intelligence /marketintelligence/en/news-insights/trending/mrwg4lcynp1ucwbg6iorig2 content esgSubNav
In This List

Indivior sues generic makers over anti-opioid medication patent

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Indivior sues generic makers over anti-opioid medication patent

Indivior PLC has filed lawsuits in the U.S. against a number of generic makers over a patent covering Suboxone, a treatment for opioid addiction.

Among those sued are Dr. Reddy's Laboratories Ltd., Alvogen Inc. and Teva Pharmaceutical Industries Ltd.

The lawsuits, filed by the company's Richmond, Va.-based unit Indivior Inc., claim the companies infringe a patent which was granted to it on Jan. 2.

"We believe this new patent is strong and we are asserting it in order to protect our intellectual property rights," Indivior CEO Shaun Thaxter said in a news release.

The company brought similar patent cases in 2017, losing to Dr. Reddy's and settling with Mylan NV.